Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sell transaction in company stock. On June 17, 2026, he exercised stock options to acquire a total of 10,522 shares of Common Stock at an exercise price of $46.54 per share.
On the same date he sold 10,462 shares in open-market transactions at weighted average prices around $78.50–$79.25 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,272 shares of PTC Therapeutics common stock.
Filer submitted a Form 144 notice to sell common stock of PTCT. The filing lists 23,749 shares to be sold in a stock option exercise transaction on 06/22/2026. The excerpt also shows a prior sale of 52,003 shares on 04/01/2026 and a reported figure of 82,949,338 shares shown with the date 06/22/2026.
PTC Therapeutics, Inc. completed a private offering of $550,000,000 aggregate principal amount of 0.0% Convertible Senior Notes due 2031. The notes carry no regular interest, may only bear special interest in limited circumstances, and mature on June 15, 2031 unless earlier converted, redeemed or repurchased.
The notes are initially convertible at 9.3042 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $107.48 per share. PTC estimates net proceeds of about $535.5 million and is using approximately $328.8 million to repurchase for cash $222.0 million principal of its 1.50% Convertible Senior Notes due 2026, leaving $55.5 million of those existing notes outstanding. The new notes are senior unsecured obligations with customary conversion, redemption, repurchase and default provisions.
PTCT insider filing reports a proposed sale of 10,522 shares via a stock option exercise on 06/17/2026. The filing also lists prior dispositions by Mark Boulding of 2,265, 3,540 and 2,812 shares on 04/06/2026, 05/08/2026 and 05/15/2026, respectively. The exercise method is listed as cash.
PTC Therapeutics has priced a private Offering of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031, with an option for initial purchasers to buy an additional $50.0 million. PTC estimates net proceeds of about $486.8 million (or $535.5 million if the option is fully exercised).
The company expects to use approximately $328.8 million of the proceeds to repurchase for cash $222.0 million principal amount of its 1.5% Convertible Senior Notes due 2026, and to use the remainder for general corporate purposes, including potential additional 2026 note repurchases and repayment at maturity. The Notes mature on June 15, 2031, carry no coupon, and are convertible at an initial rate of 9.3042 shares per $1,000, implying a conversion price of about $107.48 per share, a roughly 40% premium to the $76.77 closing share price on June 15, 2026.
PTC Therapeutics chief business officer Eric Pauwels exercised stock options and sold shares in pre-planned trades. On June 10, 2026, he exercised options to acquire 17,566 shares of Common Stock at $18.01 per share, then executed open-market sales totaling 21,277 shares at $75.00 per share. Following these transactions, he held 73,411 shares of Common Stock directly. The trades were carried out under a written Rule 10b5-1 plan adopted on February 25, 2026, indicating they were pre-scheduled rather than timed discretionarily.
PTCT affiliate submitted a Form 144 notice to sell securities on 06/10/2026. The filing lists 17,566 shares tied to a Stock Option Exercise and 3,711 shares tied to Restricted Stock Vesting, with a broker listed as Fidelity Brokerage Services LLC.
PTC Therapeutics reports that board member Alethia Young resigned from its board of directors effective June 8, 2026. She stated that the decision reflects the need to focus on other work commitments and was not due to any disagreement with the company.
On the same date, Young entered into a Consulting Agreement under which she will continue as an advisor to PTC Therapeutics through June 8, 2027. For these advisory services, she will receive a monthly consulting fee of $4,166.67, as detailed in Exhibit 10.1 to the report.
PTC Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. As of the April 10, 2026 record date, 82,911,783 common shares were outstanding, with each share entitled to one vote.
Stockholders elected four Class I directors to serve until the 2029 annual meeting: Jessica Chutter, Matthew B. Klein, M.D., M.S., F.A.C.S., Stephanie S. Okey, M.S., and Jerome B. Zeldis, M.D., Ph.D., each receiving over 68.9 million votes “For.”
Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, with 76,170,292 votes “For.” A non-binding advisory vote on named executive officer compensation was also approved, receiving 71,166,204 votes “For.”